J&J shrugs off deals with Aduro that were worth up to $1.2B. Set­back forces shift to No­var­tis al­liance now

Back in the spring of 2014, J&J inked the first of two li­cens­ing pacts for the year with Aduro, look­ing to ben­e­fit from the biotech’s ap­proach to treat­ing can­cer. Al­to­geth­er the phar­ma gi­ant con­tributed a $30 mil­lion up­front, eq­ui­ty mon­ey as well as up to $1.2 bil­lion in mile­stones.

And in one swift move they wiped the ta­ble clean last week and walked.

Post­ed in­side an SEC fil­ing, Aduro not­ed that J&J told them they were bow­ing out on Sep­tem­ber 25. ADU-214, ADU-741 and GVAX Prostate will soon re­vert back to Aduro, as J&J al­so aban­dons any rights to its at­ten­u­at­ed Lis­te­ria tech for lung and prostate can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.